David A. Egan

8.5k citations

88 papers · 6.9k · 3 hit papers · h-index 33

Impact in

Cancer Research top 1%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Cancer Genomics and Diagnostics
Oncology top 1%
- Cancer Cells and Metastasis

Papers in

Molecular Biology 53
- Signaling Pathways in Disease 6
- Receptor Mechanisms and Signaling 6
- Epigenetics and DNA Methylation 5
Oncology 17
- Cancer Cells and Metastasis 4
- Cancer-related Molecular Pathways 4

Co-authors: Remco Nagel (2 shared papers)Carlos le Sage (2 shared papers)Mariëtte Schrier (2 shared papers)Reuven Agami (2 shared papers)Ronald Evans (3 shared papers)Thomas F. Holzman (12 shared papers)Elly Mesman (1 shared paper)Silvia Anna Ciafrè (1 shared paper)
Journals: Journal of Medicinal Chemistry (9 papers)Biochemistry (5 papers)Assay and Drug Development Technologies (4 papers)Proceedings of the National Academy of Sciences (3 papers)SLAS DISCOVERY (3 papers)
Partner nations: United States Netherlands United Kingdom

In The Last Decade

David A. Egan

86 papers receiving 6.7k citations

David A. Egan's Hit Papers

align trajectories log scale

Intra-tumour diversification in colorectal cancer at the single-cell level 2018 · 433 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2018 Nature
2017 Cell
2008 Nature Cell Biology

Peers

Countries citing papers authored by David A. Egan

Since Specialization

Citations

This map shows the geographic impact of David A. Egan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Egan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Egan more than expected).

Fields of papers citing papers by David A. Egan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Egan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Egan. The network helps show where David A. Egan may publish in the future.

Co-authors

The 25 scholars most cited alongside David A. Egan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David A. Egan Line = papers co-authored together David A. Egan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 88 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity Cell ·Norman Sachs, Joep de Ligt, Oded Kopper, Ewa Gogola, Gergana Bounova, Fleur Weeber, Anjali Vanita Balgobind, Karin Wind-Mark Hit paper breakdown →	2017	1520
2	The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis Nature Cell Biology ·Qihong Huang, Kiranmai Gumireddy, Mariëtte Schrier, Carlos le Sage, Remco Nagel, Suresh Gangadharan Nair, David A. Egan, An‐Ping Li Hit paper breakdown →	2008	854
3	Regulation of the p27Kip1 tumor suppressor by miR‐221 and miR‐222 promotes cancer cell proliferation The EMBO Journal ·Carlos le Sage, Remco Nagel, David A. Egan, Mariëtte Schrier, Elly Mesman, Annunziato Mangiola, C. Anile, Giulio Maira	2007	703
4	Intra-tumour diversification in colorectal cancer at the single-cell level Nature ·Sophie F. Roerink, Nobuo Sasaki, Henry Lee-Six, Matthew D. Young, Ludmil B. Alexandrov, Sam Behjati, Thomas J. Mitchell, Sebastian Großmann Hit paper breakdown →	2018	433
5	Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1 Nature ·Coenraad P. Kuijl, Nigel D. L. Savage, Marije Marsman, Adriaan Willem Tuin, Lennert Janssen, David A. Egan, Mirjam Ketema, Rian van den Nieuwendijk	2007	267
6	Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening eLife ·Carla S. Veríssimo, René Overmeer, Bas Ponsioen, Jarno Drost, Sander Mertens, Ingrid Verlaan-Klink, Bastiaan van Gerwen, Marieke van de Ven	2016	214
7	Kringle 5 of Human Plasminogen Induces Apoptosis of Endothelial and Tumor Cells through Surface-Expressed Glucose-Regulated Protein 78 Cancer Research ·Donald J. Davidson, Catherine J. Haskell, Sandy Majest, Abdullah Kherzai, David A. Egan, Karl A. Walter, Andrew J. Schneider, Earl Gubbins	2005	208
8	Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation Proceedings of the National Academy of Sciences ·Harald M. H. G. Albers, Anping Dong, Laurens A. van Meeteren, David A. Egan, Manjula Sunkara, Erica W. van Tilburg, Karianne G. Schuurman, Olaf van Tellingen	2010	175
9	NMR studies of [U-13C] cyclosporin A bound to cyclophilin: bound conformation and portions of cyclosporin involved in binding Biochemistry ·Stephen W. Fesik, Robert T. Gampe, Hugh L. Eaton, Gerd Gemmecker, Edward T. Olejniczak, Placido Neri, Thomas F. Holzman, David A. Egan	1991	163
10	Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling Proceedings of the National Academy of Sciences ·Vassilis Doucas, Marc Tini, David A. Egan, Ronald Evans	1999	152
11	NMR-Based Discovery of Lead Inhibitors That Block DNA Binding of the Human Papillomavirus E2 Protein Journal of Medicinal Chemistry ·Philip J. Hajduk, Jürgen Dinges, Gregory F. Miknis, Megan Merlock, Tim R. Middleton, Dale J. Kempf, David A. Egan, Karl A. Walter	1997	138
12	In vitro induction of alkaline phosphatase levels predicts in vivo bone forming capacity of human bone marrow stromal cells Stem Cell Research ·Henk‐Jan Prins, Arie Koen Braat, Debby Gawlitta, Wouter J.A. Dhert, David A. Egan, Estel Tijssen-Slump, Huipin Yuan, Paul James Coffer	2013	137
13	A Genome-wide Multidimensional RNAi Screen Reveals Pathways Controlling MHC Class II Antigen Presentation Cell ·Petra Paul, Tineke van den Hoorn, Marlieke L.M. Jongsma, Mark J. Bakker, Rutger C.C. Hengeveld, Lennert Janssen, Peter Cresswell, David A. Egan	2011	119
14	Isotope-Edited NMR of Cyclosporin a Bound to Cyclophilin: Evidence for a Trans 9,10 Amide Bond Science ·Stephen W. Fesik, Robert T. Gampe, Thomas F. Holzman, David A. Egan, Rohinton P. Edalji, Jay R. Luly, Robert L. Simmer, Rosalind J. Helfrich	1990	101
15	Molecular genetics of acute promyelocytic leukemia Trends in Genetics ·Richard Jirui Lin, David A. Egan, Ronald Evans	1999	101
16	Physiologically Relevant Metal Cofactor for Methionine Aminopeptidase-2 Is Manganese Biochemistry ·Jieyi Wang, George S. Sheppard, Pingping Lou, Megumi Kawai, Chang Y. Park, David A. Egan, Andrew J. Schneider, Jennifer J. Bouska	2003	96
17	A High-Throughput Pharmaceutical Screen Identifies Compounds with Specific Toxicity against BRCA2-Deficient Tumors Clinical Cancer Research ·Bastiaan Evers, Eva Schut, Eline van der Burg, Tanya M. Braumuller, David A. Egan, Henne H. Holstege, Pauline A. H. Edser, David J. Adams	2009	69
18	Discovery and Optimization of Boronic Acid Based Inhibitors of Autotaxin Journal of Medicinal Chemistry ·Harald M. H. G. Albers, Laurens A. van Meeteren, David A. Egan, Erica W. van Tilburg, Wouter H. Moolenaar, Huib Ovaa	2010	65
19	Purification and characterization of the mammalian .beta.2-adrenergic receptor Biochemistry ·C J Homcy, Stanley G. Rockson, J L Countaway, David A. Egan	1983	62
20	Renin inhibitors. Dipeptide analogs of angiotensinogen utilizing a dihydroxyethylene transition-state mimic at the scissile bond to impart greater inhibitory potency Journal of Medicinal Chemistry ·Jay R. Luly, Nwe Y. BaMaung, Jeff Soderquist, Anthony K. L. Fung, Hollis D. Kleinert, Patrick A. Marcotte, David A. Egan, Barbara A. Bopp +1 other	1988	56

About David A. Egan

David A. Egan is a scholar working on Molecular Biology, Oncology, Biophysics, Cancer Research and Cell Biology, having authored 88 papers that have together received 6.9k indexed citations. Recurring topics across this work include Cell Image Analysis Techniques (8 papers), Renin-Angiotensin System Studies (7 papers), Signaling Pathways in Disease (6 papers), Receptor Mechanisms and Signaling (6 papers), Epigenetics and DNA Methylation (5 papers), Endoplasmic Reticulum Stress and Disease (4 papers), Cancer Cells and Metastasis (4 papers) and Cancer-related Molecular Pathways (4 papers). The work is most often cited by research in Cancer Research (2.0k citations), Oncology (2.0k citations), Molecular Biology (3.9k citations), Cell Biology (528 citations) and Immunology (601 citations). David A. Egan has collaborated with scholars based in United States, Netherlands and United Kingdom. Frequent co-authors include Remco Nagel, Carlos le Sage, Mariëtte Schrier, Reuven Agami, Ronald Evans, Thomas F. Holzman, Elly Mesman, Silvia Anna Ciafrè, Neri Mercatelli and Giulio Maira. Their work appears in journals such as Journal of Medicinal Chemistry, Biochemistry, Assay and Drug Development Technologies, Proceedings of the National Academy of Sciences and SLAS DISCOVERY.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

David A. Egan

Impact in

Papers in i

In The Last Decade

David A. Egan

David A. Egan's Hit Papers

Peers

Countries citing papers authored by David A. Egan

Fields of papers citing papers by David A. Egan

All Works

About David A. Egan

Explore authors with similar magnitude of impact

Papers in